All In Biotech

Drug Trial Radar · NCT04910685

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 534 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

534

Planned (sponsor's estimate)

Start

Nov 30, 2021

Primary completion

Sep 30, 2032

Study completion Sep 30, 2032

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.

Conditions

  • Indolent Systemic Mastocytosis
  • Smoldering Systemic Mastocytosis

Interventions

  • ElenestinibDrug

    Elenestinib oral tablet

  • PlaceboDrug

    Placebo oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 12 weeks
  2. Part 1: Mean change from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS)Time frame: Baseline, Week 13
  3. Part 2: Mean change from baseline in ISM-SAF TSSTime frame: Baseline, Week 49
  4. Part 3: Number of participants with Adverse Events (AEs)Time frame: Up to 5 years
  5. Part 3: Change from baseline in ISM-SAF TSSTime frame: Baseline up to 5 years

Locations

88 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Orso Health, Modena Allergy and Asthma Inc

    La Jolla, California · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute

    Palo Alto, California · Recruiting

  • UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Michigan Medicine University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Roswell Park Cancer Institute

    Buffalo, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Duke Asthma, Allergy and Airway Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • CHP Centro Hematologico Pavlovsky

    Buenos Aires, Argentina · Recruiting

  • Consultorios Medicos Dr. Doreski - Fundacion Respirar

    Buenos Aires, Argentina · Recruiting

  • The Canberra Hospital

    Garran, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Kepler Universitatsklinikum, Med Campus III. Clinic of Internal Medicine 3 - Hematology and Oncology

    Linz, Austria · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • CHU Tivoli

    La Louvière, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Unitversitair Ziekenhuis Antwerpen

    Edegem, Antwerpen, Belgium · Recruiting

  • Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP

    São Paulo, Brazil · Recruiting

  • Clinica Alemana de Santiago

    Santiago, Chile · Recruiting

  • Fundación Valle del Lili

    Cali, Colombia · Recruiting

  • Fakultní nemocnice Brno, Interní hematologická a onkologická klinika

    Brno, Czechia · Recruiting

  • Fakultní nemocnice Královské Vinohrady, Hematologická klinika 3. LF UK v Praze a FNKV

    Prague, Czechia · Recruiting

  • Odense University Hospital and University of Southern Denmark

    Odense, Denmark · Recruiting

  • CHU Amiens-Picardie

    Amiens, France · Recruiting

  • CHU de Caen

    Caen, France · Recruiting

  • CHU Grenoble

    Grenoble, France · Recruiting

  • CHU de Limoges

    Limoges, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Hôpital de la Pitié Salpétrière

    Paris, France · Recruiting

  • Hôpital Necker - Départementd 'HématologieA dultes

    Paris, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

  • CHU Toulouse - Hopital Larrey

    Toulouse, France · Recruiting

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.